Sherman SK, et al. - From a Medicare payer’s perspective, researchers determined the impact of capecitabine and bevacizumab drug prices on cost-effectiveness. For payers and society, antineoplastic therapy is expensive. Total drug costs must be reduced from $6173 to $452 per 3-week chemotherapy cycle in order to reduce the cost to $59,039 per unadjusted life-year. They found that the unadjusted ratio was $438 394 per life-year. The price of capecitabine and bevacizumab maintenance treatment should be reduced by 93% to make it cost-effective, a useful finding for policy decision making and payment negotiations.